发布日期：2009-01-09
英文标题：Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized,placebo-controlled trial.
作者：Jean-Claude Tardif
出处：European Heart Journal , 2009 , 30 (5) :540
内容介绍：一项历时 4 个月的随机安慰剂对照试验，评价接受β受体阻滞剂治疗的慢性稳定型心绞痛患者接受 If 电流抑制剂伊伐布雷定的抗心绞痛和抗缺血疗效。
摘要展示：
Aims : To evaluate the anti-anginal and anti-ischaemic efficacy of the selective If current inhibitor ivabradine in patients with chronic stable angina pectoris receiving beta-blocker therapy.
Methods and results: In this double-blinded trial, 889 patients with stable angina receiving atenolol 50 mg/day were randomized to receive ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months, or placebo. Patients underwent treadmill exercise tests at the trough of drug activity using the standard Bruce protocol for randomization and at 2 and 4 months. Total exercise duration at 4 months increased by 24.3+65.3 s in the ivabradine group, compared with 7.7+63.8 s with placebo (P , 0.001). Ivabradine was superior to placebo for all exercise test criteria at 4 months (P , 0.001 for all) and 2 months (P-values between ,0.001 and 0.018). Ivabradine in combination with atenolol was well tolerated. Only 1.1% of patients withdrew owing to sinus bradycardia in the ivabradine group.
Conclusion: The combination of ivabradine 7.5 mg b.i.d. and atenolol at the commonly used dosage in clinical practice in patients with chronic stable angina pectoris produced additional efficacy with no untoward effect on safety or tolerability.
